Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.
In breast cancer patients undergoing neoadjuvant chemotherapy before surgery, there is an unmet need for non-invasive biomarkers predictive of response. Analysis of DNA circulating tumor (ctDNA) in particular has been the object of several reports, but some of them have studied the application of targeted sequencing marked in (tTDS) for clinical practice and performance compared …